Opinion|Videos|April 11, 2025
The Metro Nashville Public Schools Initiative
Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to overcome cost-related barriers, explore strategies other payers could adopt based on the success of Metro Nashville Public Schools' initiative to provide CGM devices without prior authorization, and examine the impact of removing prior authorization requirements on appropriate patient selection and utilization, along with which aspects of this model could be adopted by other employers and the resources needed to implement similar programs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you evaluate and communicate the return on investment for CGM coverage to help overcome cost-related barriers?
- Based on the success of Metro Nashville Public Schools'
initiative to provide CGM devices without prior authorization, what which strategies could other payers adopt, and what challenges might arise in scaling these efforts? - Based on the success of removing prior authorization requirements in the Metro Nashville initiative:
- How did this change impact appropriate patient selection and utilization?
- What Which specific aspects of this model could other employers adopt?
- What resources or support would employers need to implement similar programs?
Advertisement
Related to this article
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5